PCRX
Pacira BioSciences, Inc. NASDAQ Listed Feb 3, 2011$22.33
-1.37%
vs $22.64
Mkt Cap $1.0B
52w Low $19.16
39.3% of range
52w High $27.22
50d MA $23.63
200d MA $23.50
P/E (TTM)
139.6x
EV/EBITDA
9.9x
P/B
1.4x
Debt/Equity
0.7x
ROE
1.0%
P/FCF
7.4x
RSI (14)
36.90
ATR (14)
$0.74
Beta
0.20
50d MA
$23.63
200d MA
$23.50
Avg Volume
472.3K
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
5401 West Kennedy Boulevard · Tampa, FL 33609 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | 0.61 | 0.60 | -1.6% | 25.49 | +5.5% | -4.1% | +1.0% | +0.4% | -4.4% | -0.2% | — |
| Feb 26, 2026 | AMC | 0.85 | 0.57 | -32.9% | 22.59 | -6.4% | -3.0% | -2.9% | +3.9% | +3.4% | +0.0% | — |
| Nov 6, 2025 | AMC | 0.65 | 0.70 | +7.7% | 21.10 | -3.7% | +4.5% | +4.6% | +4.6% | -1.1% | -1.0% | — |
| Aug 5, 2025 | AMC | 0.72 | 0.74 | +2.8% | 22.54 | -1.3% | -0.6% | +6.1% | +5.9% | +0.0% | -1.5% | — |
| May 8, 2025 | AMC | 0.57 | 0.62 | +8.8% | 24.91 | -7.7% | +0.8% | -0.1% | -6.7% | +4.5% | +4.7% | — |
| Feb 27, 2025 | AMC | 0.78 | 0.91 | +16.7% | 25.38 | +2.4% | -5.2% | -4.5% | +2.5% | -0.1% | +1.5% | — |
| Nov 6, 2024 | AMC | 0.72 | 0.79 | +9.7% | 17.67 | -0.5% | +0.2% | -2.6% | +1.5% | -4.0% | -2.1% | — |
| Jul 30, 2024 | AMC | 0.73 | 0.89 | +21.9% | 19.54 | +13.6% | +5.7% | +0.5% | +2.5% | -5.1% | +7.1% | — |
| May 7, 2024 | AMC | 0.64 | 0.62 | -3.1% | 26.51 | +9.0% | +11.8% | +0.7% | -1.5% | +3.3% | +1.4% | — |
| Feb 29, 2024 | AMC | 0.89 | 0.89 | +0.0% | 29.72 | -0.1% | -2.9% | +1.2% | +0.8% | +2.3% | +1.8% | — |
| Nov 2, 2023 | AMC | 0.84 | 0.72 | -14.3% | 29.19 | +2.0% | +6.3% | -1.0% | -1.5% | -1.2% | -5.0% | — |
| Aug 2, 2023 | AMC | 0.81 | 0.78 | -3.7% | 36.71 | +2.1% | +5.6% | +1.9% | -3.4% | +0.1% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Needham | Maintains | Buy → Buy | — | $25.49 | $26.90 | +5.5% | -4.1% | +1.0% | +0.4% | -4.4% | -0.2% |
| May 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $25.49 | $26.90 | +5.5% | -4.1% | +1.0% | +0.4% | -4.4% | -0.2% |
| Mar 26 | Barclays | Maintains | Equal Weight → Equal Weight | — | $23.49 | $23.27 | -0.9% | -0.8% | -1.8% | +1.7% | -2.9% | +0.8% |
| Jan 9 | Needham | Maintains | Buy → Buy | — | $26.02 | $24.64 | -5.3% | -9.6% | -2.5% | -5.8% | +3.0% | -7.1% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.02 | $24.64 | -5.3% | -9.6% | -2.5% | -5.8% | +3.0% | -7.1% |
| Nov 7 | Truist | Maintains | Buy → Buy | — | $21.10 | $20.32 | -3.7% | +4.5% | +4.6% | +4.6% | -1.1% | -1.0% |
| May 9 | Needham | Maintains | Buy → Buy | — | $24.91 | $23.00 | -7.7% | +0.8% | -0.1% | -6.7% | +4.5% | +4.7% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $22.91 | $27.60 | +20.5% | +14.7% | -1.6% | -8.3% | +3.7% | +1.7% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.91 | $27.60 | +20.5% | +14.7% | -1.6% | -8.3% | +3.7% | +1.7% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.38 | $26.00 | +2.4% | -5.2% | -4.5% | +2.5% | -0.1% | +1.5% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $25.38 | $26.00 | +2.4% | -5.2% | -4.5% | +2.5% | -0.1% | +1.5% |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | $25.38 | $26.00 | +2.4% | -5.2% | -4.5% | +2.5% | -0.1% | +1.5% |
| Jan 30 | Truist | Upgrade | Sell → Hold | — | $26.03 | $27.00 | +3.7% | +0.8% | +0.3% | -2.2% | +3.3% | +1.9% |
| Jan 14 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $21.13 | $21.12 | -0.0% | -2.7% | +6.5% | +0.8% | +1.4% | +2.1% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $20.64 | $21.01 | +1.8% | +2.4% | -2.7% | +6.5% | +0.8% | +1.4% |
| Dec 17 | Needham | Maintains | Buy → Buy | — | $19.87 | $19.72 | -0.8% | -0.2% | -3.2% | +2.0% | -3.0% | +1.2% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.68 | $16.71 | +0.2% | +14.4% | -2.2% | +3.2% | -0.9% | +3.5% |
| Nov 12 | Barclays | Maintains | Equal Weight → Equal Weight | — | $17.50 | $17.13 | -2.1% | -4.0% | -2.1% | -0.5% | +1.4% | +0.2% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $17.70 | $17.59 | -0.6% | -2.6% | +1.5% | -4.0% | -2.1% | -0.5% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $17.67 | $17.58 | -0.5% | +0.2% | -2.6% | +1.5% | -4.0% | -2.1% |
| Oct 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $15.89 | $16.05 | +1.0% | +4.0% | -3.2% | -2.1% | -0.5% | -0.4% |
| Sep 24 | Jefferies | Maintains | Buy → Buy | — | $14.28 | $14.45 | +1.2% | -0.1% | -2.5% | +3.0% | +1.5% | +3.5% |
| Aug 13 | Truist | Downgrade | Buy → Sell | — | $12.29 | $11.55 | -6.0% | +0.9% | +0.6% | +7.1% | -3.1% | +8.0% |
| Aug 12 | JP Morgan | Downgrade | Overweight → Underweight | — | $11.70 | $12.06 | +3.1% | +5.0% | +0.9% | +0.6% | +7.1% | -3.1% |
| Aug 12 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $11.70 | $12.06 | +3.1% | +5.0% | +0.9% | +0.6% | +7.1% | -3.1% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.70 | $12.06 | +3.1% | +5.0% | +0.9% | +0.6% | +7.1% | -3.1% |
| Aug 12 | Needham | Maintains | Buy → Buy | — | $11.70 | $12.06 | +3.1% | +5.0% | +0.9% | +0.6% | +7.1% | -3.1% |
| Aug 1 | Jefferies | Maintains | Buy → Buy | — | $20.65 | $20.85 | +1.0% | +0.5% | +2.5% | -5.1% | +7.1% | +3.3% |
| Jul 31 | RBC Capital | Maintains | Outperform → Outperform | — | $19.54 | $22.19 | +13.6% | +5.7% | +0.5% | +2.5% | -5.1% | +7.1% |
| Jul 31 | Needham | Maintains | Buy → Buy | — | $19.54 | $22.19 | +13.6% | +5.7% | +0.5% | +2.5% | -5.1% | +7.1% |
| Jul 31 | Raymond James | Maintains | Outperform → Outperform | — | $19.54 | $22.19 | +13.6% | +5.7% | +0.5% | +2.5% | -5.1% | +7.1% |
| Jul 25 | Truist | Maintains | Buy → Buy | — | $20.26 | $20.23 | -0.1% | -1.4% | +0.3% | +1.6% | -4.0% | +5.7% |
| Jul 3 | Barclays | Downgrade | Overweight → Equal Weight | — | $22.74 | $21.71 | -4.5% | -4.7% | -2.8% | -2.2% | +1.7% | -3.0% |
| Jul 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $22.74 | $21.71 | -4.5% | -4.7% | -2.8% | -2.2% | +1.7% | -3.0% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.46 | $28.25 | -0.7% | -20.1% | -4.7% | -2.8% | -2.2% | +1.7% |
| Jul 2 | Needham | Maintains | Buy → Buy | — | $28.46 | $28.25 | -0.7% | -20.1% | -4.7% | -2.8% | -2.2% | +1.7% |
| May 8 | Needham | Maintains | Buy → Buy | — | $26.51 | $28.90 | +9.0% | +11.8% | +0.7% | -1.5% | +3.3% | +1.4% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.51 | $28.90 | +9.0% | +11.8% | +0.7% | -1.5% | +3.3% | +1.4% |
| May 8 | Barclays | Maintains | Overweight → Overweight | — | $26.51 | $28.90 | +9.0% | +11.8% | +0.7% | -1.5% | +3.3% | +1.4% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $28.48 | $28.60 | +0.4% | +0.1% | -2.4% | -1.7% | -1.9% | -1.1% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.86 | $28.40 | -1.6% | +1.2% | +0.8% | +2.3% | +1.8% | +2.5% |
| Mar 1 | Needham | Maintains | Buy → Buy | — | $29.72 | $29.69 | -0.1% | -2.9% | +1.2% | +0.8% | +2.3% | +1.8% |
| Mar 1 | RBC Capital | Maintains | Outperform → Outperform | — | $29.72 | $29.69 | -0.1% | -2.9% | +1.2% | +0.8% | +2.3% | +1.8% |
| Feb 8 | Wedbush | Maintains | Outperform → Outperform | — | $28.49 | $28.55 | +0.2% | -2.8% | +3.9% | +4.3% | -2.7% | +0.1% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.04 | $30.79 | -0.8% | -1.0% | -1.5% | -1.2% | -5.0% | +0.2% |
| Nov 3 | RBC Capital | Maintains | Outperform → Outperform | — | $29.19 | $29.76 | +2.0% | +6.3% | -1.0% | -1.5% | -1.2% | -5.0% |
| Nov 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.19 | $29.76 | +2.0% | +6.3% | -1.0% | -1.5% | -1.2% | -5.0% |
| Nov 3 | Needham | Maintains | Buy → Buy | — | $29.19 | $29.76 | +2.0% | +6.3% | -1.0% | -1.5% | -1.2% | -5.0% |
| Oct 23 | Barclays | Maintains | Overweight → Overweight | — | $28.51 | $28.29 | -0.8% | -1.8% | +0.7% | -3.5% | +0.2% | +1.0% |
| Oct 3 | RBC Capital | Maintains | Outperform → Outperform | — | $29.86 | $29.78 | -0.3% | -2.1% | -2.0% | +1.4% | +2.5% | +1.5% |
No insider trades available.
8-K · 5.02
!!! Very High
Pacira BioSciences, Inc. -- 8-K 5.02: Executive Change
Pacira BioSciences increased its employee stock purchase plan by 800,000 shares, enabling broader employee equity participation and potential dilution to existing shareholders.
Jun 11
8-K
Pacira BioSciences, Inc. -- 8-K Filing
Pacira BioSciences reported record-high EXPAREL sales with 7% volume growth in Q4, its strongest quarter in three years, signaling robust market demand for its flagship anesthetic product.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 2,385,188 | $62M | Added | Dec 2025 |
| 2 | Vanguard Portfolio Management Llc | 2,501,286 | $57M | New | Mar 2026 |
| 3 | D.e. Shaw & Co | 1,982,724 | $45M | Reduced | Mar 2026 |
| 4 | Renaissance Technologies Llc | 1,825,501 | $41M | Reduced | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 1,784,049 | $40M | New | Mar 2026 |
| 6 | Impax Asset Management Group Plc | 750,027 | $19M | Added | Dec 2025 |
| 7 | Citadel Advisors Llc | 797,281 | $18M | Reduced | Mar 2026 |
| 8 | Ubs Group Ag | 562,040 | $13M | Added | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 526,851 | $12M | Added | Mar 2026 |
| 10 | Northern Trust Corp | 519,412 | $12M | Reduced | Mar 2026 |
| 11 | Jane Street Group, Llc | 385,984 | $10M | Added | Dec 2025 |
| 12 | Easterly Investment Partners Llc | 334,854 | $8M | Added | Mar 2026 |
| 13 | Phocas Financial Corp. | 293,070 | $8M | — | Dec 2025 |
| 14 | Bank Of New York Mellon Corp | 302,629 | $7M | Reduced | Mar 2026 |
| 15 | First Trust Advisors Lp | 300,632 | $7M | Added | Mar 2026 |
| 16 | Principal Financial Group Inc | 261,388 | $7M | Added | Dec 2025 |
| 17 | Barclays Plc | 282,108 | $6M | Reduced | Mar 2026 |
| 18 | Jpmorgan Chase & Co | 240,369 | $6M | Reduced | Mar 2026 |
| 19 | Invesco Ltd. | 237,580 | $5M | Reduced | Mar 2026 |
| 20 | Victory Capital Management Inc | 235,090 | $5M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.01B
Enterprise Value
$1.18B
P/E (TTM)
139.56x
Forward P/E
8.51x
PEG Ratio
-1.53x
P/B
1.44x
P/S
1.38x
P/FCF
7.36x
EV/EBITDA
9.87x
Shares Out
45.0M
Financials (TTM)
Revenue
$726.4M
Net Income
$7.0M
EBITDA
$119.1M
Free Cash Flow
$136.7M
Op Cash Flow
$152.0M
EPS Basic
$0.16
EPS Diluted
$0.16
EPS Forward
$2.62
Gross Margin
71.5%
Op Margin
3.9%
Net Margin
1.0%
Balance Sheet
Total Assets
$1.26B
Total Liab.
$571.8M
Total Equity
$693.1M
Cash
$238.4M
LT Debt
$408.4M
Book Value/Sh
$15.55
Debt/Equity
0.66x
Current Ratio
4.54
Quick Ratio
3.28
Returns & Growth
ROE
1.0%
ROA
0.6%
ROIC
1.0%
Rev Growth YoY
+3.6%
EPS Growth YoY
+107.4%
Price Returns
2W
-1.3%
1M
-8.9%
3M
+6.0%
6M
-1.5%
12M
-10.1%
Technicals
52W High
$27.22
52W Low
$19.16
50d MA
$23.63
200d MA
$23.50
RSI (14)
36.90
ATR (14)
$0.74
Beta
0.20
Avg Volume
472K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$27.00
High
$27.00
Low
$27.00
Median
$27.00
Data updated apr 26, 2026 6:58pm
· Source: financialmodelingprep.com